FibroGen Inc (NAS:FGEN)
$ 1.3 0.02 (1.56%) Market Cap: 129.32 Mil Enterprise Value: 101.67 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 57/100

FibroGen Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 16, 2020 / 07:30PM GMT
Release Date Price: $45.02 (+2.16%)
Albert Hwang;Morgan Stanley;Managing Director

Good afternoon, everybody. Thank you for joining. This is the FibroGen fireside chat. I'm Albert Hwang from Morgan Stanley. Thanks for being at the conference. And I'd like to introduce the CEO of FibroGen, Enrique Conterno, who -- maybe you can give a couple of minute overview on how things are going with the company. And then we can get started with questions. Enrique?

Enrique A. Conterno
FibroGen, Inc. - CEO & Director

Very good. Thank you, Albert. Thank you very much for the invitation. We have an exciting agenda here at FibroGen. Clearly, roxadustat being commercialized in China and Japan, very much undergoing the final stages of the regulatory review in the United States, submission in Europe. Clearly, a transformational medicine when it comes to CKD anemia.

We are making progress with pamrevlumab on enrollments on a collective of high need medical indications whether it's IPF or LAPC or DMD. So now we basically have Phase III programs in each one of those indications.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot